Literature DB >> 24670150

The MCH(1) receptor, an anti-obesity target, is allosterically inhibited by 8-methylquinoline derivatives possessing subnanomolar binding and long residence times.

T Sakurai1, K Ogawa, Y Ishihara, S Kasai, M Nakayama.   

Abstract

BACKGROUND AND
PURPOSE: Melanin-concentrating hormone receptor 1 (MCH1 receptor) antagonists are being considered as anti-obesity agents. The present study reports a new class of MCH1 receptor antagonists with an 8-methylquinoline scaffold. The molecular mechanism of MCH1 receptor blockade by these antagonists was examined. EXPERIMENTAL APPROACH: The pharmacological properties of the 8-methylquinolines as exemplified by MQ1 were evaluated by use of multiple biophysical and cell-based functional assays. KEY
RESULTS: Multiple signalling pathways for Gαi and Gαq , and β-arrestin were inhibited by MQ1. Furthermore, MQ1 produced an insurmountable antagonism, causing a rightward shift of the curve for concentration-dependent binding of MCH along with a progressive reduction of the maximal response. The dissociation kinetics for MQ1 were determined from washout experiments as well as by affinity selection-MS. In short, MQ1 was shown to be a slowly dissociating reversible MCH1 receptor blocker with a low Koff value. CONCLUSION AND IMPLICATIONS: This is the first time that a slowly dissociating negative allosteric modulator of the MCH1 receptor has been demonstrated to inhibit the numerous signalling pathways of this receptor. The characteristics of MQ1 are superior and distinct from previously reported MCH1 receptor antagonists, making members of this chemotype attractive as drug candidates.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  antagonist; melanin-concentrating hormone receptor 1 (MCH1 receptor); negative allosteric modulator; obesity; slow dissociation; time-dependent inhibition

Mesh:

Substances:

Year:  2014        PMID: 24670150      PMCID: PMC3952805          DOI: 10.1111/bph.12529

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  54 in total

1.  Cloning and molecular characterization of the novel human melanin-concentrating hormone receptor MCH2.

Authors:  M Rodriguez; P Beauverger; I Naime; H Rique; C Ouvry; S Souchaud; S Dromaint; N Nagel; T Suply; V Audinot; J A Boutin; J P Galizzi
Journal:  Mol Pharmacol       Date:  2001-10       Impact factor: 4.436

2.  Cloning of a novel G protein-coupled receptor, SLT, a subtype of the melanin-concentrating hormone receptor.

Authors:  M Mori; M Harada; Y Terao; T Sugo; T Watanabe; Y Shimomura; M Abe; Y Shintani; H Onda; O Nishimura; M Fujino
Journal:  Biochem Biophys Res Commun       Date:  2001-05-25       Impact factor: 3.575

3.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers.

Authors:  Ashraf Yassen; Erik Olofsen; Raymonda Romberg; Elise Sarton; Meindert Danhof; Albert Dahan
Journal:  Anesthesiology       Date:  2006-06       Impact factor: 7.892

4.  The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety.

Authors:  Robert A Copeland
Journal:  Expert Opin Drug Discov       Date:  2010-04       Impact factor: 6.098

Review 5.  Antiobesity effects of melanin-concentrating hormone receptor 1 (MCH-R1) antagonists.

Authors:  Hyae Gyeong Cheon
Journal:  Handb Exp Pharmacol       Date:  2012

6.  Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists.

Authors:  Shigeyuki Chaki; Takeo Funakoshi; Shiho Hirota-Okuno; Mariko Nishiguchi; Toshiharu Shimazaki; Michihiko Iijima; Andrew J Grottick; Kosuke Kanuma; Katsunori Omodera; Yoshinori Sekiguchi; Shigeru Okuyama; Thuy-Anh Tran; Graeme Semple; William Thomsen
Journal:  J Pharmacol Exp Ther       Date:  2005-01-26       Impact factor: 4.030

7.  Molecular characterization of the melanin-concentrating hormone/receptor complex: identification of critical residues involved in binding and activation.

Authors:  D Macdonald; N Murgolo; R Zhang; J P Durkin; X Yao; C D Strader; M P Graziano
Journal:  Mol Pharmacol       Date:  2000-07       Impact factor: 4.436

8.  Biased agonism.

Authors:  Terry Kenakin
Journal:  F1000 Biol Rep       Date:  2009-11-26

9.  Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity.

Authors:  Yanyun Chen; Changzhi Hu; Chiun-Kang Hsu; Qing Zhang; Chen Bi; Mark Asnicar; Hansen M Hsiung; Niles Fox; Lawrence J Slieker; Derek D Yang; Mark L Heiman; Yuguang Shi
Journal:  Endocrinology       Date:  2002-07       Impact factor: 4.736

Review 10.  Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors.

Authors:  Eric Reiter; Seungkirl Ahn; Arun K Shukla; Robert J Lefkowitz
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011-09-19       Impact factor: 13.820

View more
  2 in total

Review 1.  Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts.

Authors:  Eric A Wold; Jianping Chen; Kathryn A Cunningham; Jia Zhou
Journal:  J Med Chem       Date:  2018-08-28       Impact factor: 7.446

2.  Computational data of phytoconstituents from Hibiscus rosa-sinensis on various anti-obesity targets.

Authors:  Sejal P Gandhi; Kiran B Lokhande; Venkateswara K Swamy; Rabindra K Nanda; Sohan S Chitlange
Journal:  Data Brief       Date:  2019-05-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.